Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer

Abstract EGFR-tyrosine kinase inhibitors (EGFR-TKIs) have achieved remarkable outcomes in the treatment of patients with EGFR-mutant non-small-cell lung cancer, but acquired resistance is still the main factor restricting their long-term use. In addition to the T790 M mutation of EGFR, amplification...

Full description

Bibliographic Details
Main Authors: Zhe Zhang, Sen Yang, Qiming Wang
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Biomarker Research
Subjects:
MET amplification
EGFR-TKIs
Resistance
Non-small cell lung cancer
Online Access:http://link.springer.com/article/10.1186/s40364-019-0179-6

Internet

http://link.springer.com/article/10.1186/s40364-019-0179-6

Similar Items